RhoBTB2 gene in breast cancer is silenced by promoter methylation

Tang,Weiwei; Wang,Chuan; Fu,Fangmeng; Chen,Qiang

doi:10.3892/ijmm.2013.1593

RhoBTB2 gene in breast cancer is silenced by promoter methylation

Authors:
- Weiwei Tang
- Chuan Wang
- Fangmeng Fu
- Qiang Chen
View Affiliations

Affiliations: Department of Oncology, Graduate School of Education, Fujian Medical University, Fuzhou, Fujian, P.R. China, Department of Galactophore Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, Fujian, P.R. China
Published online on: December 18, 2013 https://doi.org/10.3892/ijmm.2013.1593
Pages: 722-728

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mutation analysis in breast cancer has failed to explain the inactivation of RhoBTB2, a candidate breast cancer tumor suppressor gene on chromosome 8p. Some breast cancer‑related genes in this region become inactivated by hypermethylation, and hypermethylation of RhoBTB2 abrogates its expression in bladder cancers. The aim of the present study was to determine whether RhoBTB2 was silenced by methylation in breast cancer. Nested methylation‑speciﬁc PCR (nMSP) and quantitative reverse transcription PCR were used to analyze the methylation status and mRNA levels of RhoBTB2 in 50 paired breast cancer and normal tissues and the results were correlated with clinicopathological characteristics. Promoter methylation and the downregulation of RhoBTB2 mRNA was observed in tumor tissues (P<0.001). mRNA levels were decreased in samples with methylation (χ2 = 15.751, P<0.001). RhoBTB2 methylation was observed preferentially in progesterone receptor (PR)‑negative samples (P<0.05). The results demonstrated that aberrant methylation of RhoBTB2 may be responsible for the suppression of RhoBTB2 mRNA expression in breast cancer, a significant event during the genesis of breast cancer that correlated with PR status.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Jeltsch A: Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem. 3:274–293. 2002. View Article : Google Scholar : PubMed/NCBI
3	Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
4	Knowles MA, Aveyard JS, Taylor CF, Harnden P and Bass S: Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett. 225:121–130. 2005. View Article : Google Scholar : PubMed/NCBI
5	Bi Y, Zheng G, Mao HT and Zhuo WS: Anti-oncogene RhoBTB2 and breast cancer. Int J Surg. 34:177–181. 2007.
6	Hamaguchi M, Meth JL, von Klitzing C, et al: DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA. 99:13647–13652. 2002. View Article : Google Scholar
7	Chua YL, Ito Y, Pole JC, et al: The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene. 28:4041–4052. 2009. View Article : Google Scholar : PubMed/NCBI
8	Chen L, Zhu Z, Sun X, et al: Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. Breast Cancer Res Treat. 116:471–478. 2009. View Article : Google Scholar : PubMed/NCBI
9	Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J and Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene. 20:3348–3353. 2001. View Article : Google Scholar : PubMed/NCBI
10	Ferguson AT, Evron E, Umbricht CB, et al: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA. 97:6049–6054. 2000. View Article : Google Scholar : PubMed/NCBI
11	Shi Y, Chen JY, Yang J, Li B, Chen ZH and Xiao CG: DBC2 gene is silenced by promoter methylation in bladder cancer. Urol Oncol. 26:465–469. 2008. View Article : Google Scholar : PubMed/NCBI
12	Fu GP, Liao SG, Wang N and Wang YJ: The association between DBC2 gene mutation and breast cancer in Chinese population. Tumor Clin Res. 29:575–577. 2009.
13	Huang J, Zheng DL, Qin FS, et al: Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest. 120:223–241. 2010. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
15	Van Aelst L and D’Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev. 11:2295–2322. 1997.PubMed/NCBI
16	Nielsen R, Bustamante C, Clark AG, et al: A scan for positively selected genes in the genomes of humans and chimpanzees. PLoS Biol. 3:e1702005. View Article : Google Scholar : PubMed/NCBI
17	Stanelle J, Stiewe T, Theseling CC, Peter M and Putzer BM: Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 30:1859–1867. 2002. View Article : Google Scholar : PubMed/NCBI
18	D’Souza SJ, Vespa A, Murkherjee S, Maher A, Pajak A and Dagnino L: E2F-1 is essential for normal epidermal wound repair. J Biol Chem. 277:10626–10632. 2002.
19	Mao H, Qu X, Yang Y, Zuo W, Bi Y, Zhou C, Yin H, Deng B, Sun J and Zhang L: A novel tumor suppressor gene RhoBTB2 (RHOBTB2): Frequent loss of expression in sporadic breast cancer. Mol Carcinog. 49:283–289. 2010.PubMed/NCBI
20	Jones PA and Takai D: The role of DNA methylation in mammalian epigenetics. Science. 293:1068–1070. 2001. View Article : Google Scholar : PubMed/NCBI
21	Singal R and Ginder GD: DNA methylation. Blood. 93:4059–4070. 1999.PubMed/NCBI
22	Jones PA and Laird PW: Cancer-epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
23	Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
24	Fan X, Inda M, Tunon T and Castresana J: Improvement of the methylation specific PCR technical conditions for the detection of p16 promoter hypermethylation in small amounts of tumor DNA. Oncol Rep. 9:181–184. 2002.PubMed/NCBI
25	Belinsky SA, Nikula KJ, Palmisano WA, et al: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 95:11891–11896. 1998. View Article : Google Scholar : PubMed/NCBI